A577-nm Pro -Yellow Laser In Treatment of Striae Rubra

Sponsor
Al-Azhar University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05598190
Collaborator
(none)
18
1
11.5
1.6

Study Details

Study Description

Brief Summary

Stretch marks or striae are common skin condition occurring in both genders, but they are more prevalent among women. These are linear dermal scars that are accompanied by epidermal atrophy. They usually occur frequently in numerous physiological and pathological conditions, such as adolescent growth, pregnancy, obesity, Cushing disease, Marfan syndrome, and long-term systemic or topical steroid use. Decreased expression of collagen and fibronectin genes has also been associated with striae.

The pro-yellow laser systems can be used in a wide range of indications such as facial erythema, facial telangiectasia, port wine stain nevus, rosacea, poikilo derma civatte, and Becker's nevus

Some of these indications are clinical lesions in the vascular pattern; some are related to the factors that trigger vascularity, such as vascular endothelial growth factor (VEGF) in etiopathogenesis

Condition or Disease Intervention/Treatment Phase
  • Device: Pro-Yellow laser 577
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
18 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A577-nm Pro -Yellow Laser In Treatment of Striae Rubra
Actual Study Start Date :
Sep 15, 2022
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Outcome Measures

Primary Outcome Measures

  1. dermoscopic change of width of striae rubrae [1 year]

    dermoscopic photo for width of striae

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • .Patients diagnosed with striae rubera. .Age groups: at any age. .Sex : ( females).

  • Co-operative patient

Exclusion Criteria:
  • Pregnancy .

  • Patient using drugs exacerbating stria as topical or systemic steroid, and patients using other forms of treatment for stria as topical tretinoin, emollients, glycolic acid peel and laser, because that might affect the result of our study.

  • Stria Alba.

  • Skin infection (viral, bacterial or parasitic).

  • Immunosuppressed patients or with history of malignancy or radiation therapy and chronic debilitating diseases and Cushing syndrome.

  • Hypersensitivity to light and intak of photosensitizing drugs.

Contacts and Locations

Locations

Site City State Country Postal Code
1 AZHAR University Hospital Assiut Egypt

Sponsors and Collaborators

  • Al-Azhar University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Soha Alaa Abdelaal, resident doctor atD dermatology department, Al-Azhar University
ClinicalTrials.gov Identifier:
NCT05598190
Other Study ID Numbers:
  • AZ.AST./DVA021/12/211/9/2022
First Posted:
Oct 28, 2022
Last Update Posted:
Oct 28, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 28, 2022